SAN FRANCISCO - Advances in drug development have enabled scientists to attack new and unconventional cancer targets, leading to better treatments for cancer patients with fewer unwanted side effects. The following items highlight the early results from two experimental therapeutics, currently involved in Phase I or II trials, which are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
